{
    "nctId": "NCT02642406",
    "briefTitle": "Therapy Management With Nab-Paclitaxel in Daily Routine",
    "officialTitle": "Safety, Efficacy and Patient Reported Outcomes of Advanced Breast Cancer Patients: Therapy Management With Nab-Paclitaxel in Daily Routine - SERAPHINA",
    "overallStatus": "UNKNOWN",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1200,
    "primaryOutcomeMeasure": "Epidemiological assessment of progression free survival (PFS) under real life conditions.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with metastatic breast cancer in which a therapy with nab-paclitaxel was indicated by the treating physician\n* Treatment of nab-Paclitaxel must either have not been started yet, or first application of nab-Paclitaxel was not prior to 21 days before study entry\n* Female patients, age \u226518 years\n* Invasive breast cancer (irrespective of status of BC, e.g. TNM, receptor status etc.)\n* Metastatic or locally advanced, inoperable disease proven by clinical measures (i.e. standard imaging)\n* Patients scheduled for nab-Paclitaxel treatment in daily routine before screening\n* Patients, who are able and willing to sign the informed consent form\n\nExclusion Criteria:\n\n* Patient is currently enrolled, or will enroll in an interventional clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}